The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1515
Anticoagulation of Elderly Patients at High Risk for Falls with Atrial Fibrillation
The full article is available to subscribers Subscriber Login   

With the widespread adoption of the CHA2DS2-VASc scoring system,1 oral anticoagulation therapy is now recommended for all patients ≥75 years old with nonvalvular atrial fibrillation.2,3 Atrial fibrillation has, however, been associated with an increased risk of falls, and older patients starting warfarin for atrial fibrillation have a high rate of hospitalization for intracranial bleeding.4,5 Many practitioners are reluctant, therefore, to prescribe an oral anticoagulant for elderly patients who are at high risk for falls.

Most data on this subject come from patients who were treated with warfarin. The newer direct oral anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa) have been shown to be at least as ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Anticoagulation of Elderly Patients at High Risk for Falls with Atrial Fibrillation
Article code: 1515c
 Electronic, downloadable article - $25